Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded Healthcare sector company. As of July 6, 2026, AUPH trades at $15.84 with a market cap of $2.01B and a P/E ratio of 6.91. AUPH moved +1.70% today. Year to date, AUPH is -1.33%; over the trailing twelve months it is +108.41%. Its 52-week range spans $6.55 to $19.25. Analyst consensus is buy with an average price target of $15.67. Rallies surfaces AUPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for AUPH, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $15.84 |
| Market Cap | $2.01B |
| P/E Ratio | 6.91 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.25 |
| 52-Week Low | $6.55 |
| Volume | 253.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $298.30M |
| Net Income | $298.21M |
| Gross Margin | 89.74% |
3 analysts cover AUPH: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.67.